This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CTIC CTI BioPharma (CTIC) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About CTI BioPharma Stock (NASDAQ:CTIC) Get CTI BioPharma alerts:Sign Up Key Stats Today's Range$9.09▼$9.0950-Day Range$8.91▼$9.1052-Week Range$4.01▼$9.10VolumeN/AAverage Volume4.50 million shsMarket Capitalization$1.20 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an an oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. CTI BioPharma Corp. has license and collaboration agreement with Teva Pharmaceutical Industries Ltd. and S*BIO Pte Ltd. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington. Read More Receive CTIC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CTI BioPharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CTIC Stock News HeadlinesQ2 2025 Brainstorm Cell Therapeutics Inc Earnings Call TranscriptAugust 14, 2025 | gurufocus.comLineage Cell Therapeutics Inc (LCTX) Q2 2025 Earnings Call Highlights: Strategic Partnerships ...August 13, 2025 | gurufocus.comThis dark force is about to change everythingAn unstoppable force is reshaping America — one so powerful it’s already disrupting how we work, invest, and live. Porter Stansberry calls it The Final Displacement — a rare turning point that’s only happened four times in human history, each one redefining entire eras. His new documentary reveals why this shift could trigger both immense loss and unprecedented opportunity, and what you can do to prepare before it accelerates.October 22 at 2:00 AM | Porter & Company (Ad)Q2 2025 Lineage Cell Therapeutics Inc Earnings Call TranscriptAugust 12, 2025 | gurufocus.comBrainstorm Cell Therapeutics Inc (BCLI) Q1 2025 Earnings Call Highlights: Pivotal Phase 3b ...May 20, 2025 | gurufocus.comQ1 2025 Brainstorm Cell Therapeutics Inc Earnings Call TranscriptMay 20, 2025 | gurufocus.comLineage Cell Therapeutics Inc (LCTX) Q1 2025 Earnings Call Highlights: Strategic Advances and ...May 14, 2025 | gurufocus.comQ1 2025 Lineage Cell Therapeutics Inc Earnings Call TranscriptMay 13, 2025 | gurufocus.comSee More Headlines CTIC Stock Analysis - Frequently Asked Questions How were CTI BioPharma's earnings last quarter? CTI BioPharma Corp. (NASDAQ:CTIC) issued its earnings results on Monday, March, 6th. The biopharmaceutical company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.10) by $0.04. The biopharmaceutical company had revenue of $21.08 million for the quarter, compared to analysts' expectations of $24.88 million. Read the conference call transcript. When did CTI BioPharma's stock split? CTI BioPharma shares reverse split on Tuesday, January 3rd 2017.The 1-10 reverse split was announced on Friday, December 9th 2016. The number of shares owned by shareholders was adjusted after the market closes on Friday, December 30th 2016. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of CTI BioPharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that CTI BioPharma investors own include EDAP TMS (EDAP), Energous (WATT), Adverum Biotechnologies (ADVM), Weatherford International (WFT), XOMA Royalty (XOMA), Advanced Micro Devices (AMD) and Sorrento Therapeutics (SRNE). Company Calendar Last Earnings3/06/2023Today10/22/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CTIC Previous SymbolNASDAQ:CTICD CIK891293 Webwww.ctibiopharma.com Phone(206) 282-7100Fax206-284-6206Employees127Year Founded1992Profitability EPS (Trailing Twelve Months)($0.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$92.99 million Net Margins-91.38% Pretax Margin-91.38% Return on EquityN/A Return on Assets-55.82% Debt Debt-to-Equity RatioN/A Current Ratio1.27 Quick Ratio1.26 Sales & Book Value Annual Sales$53 million Price / Sales22.62 Cash FlowN/A Price / Cash FlowN/A Book Value($0.14) per share Price / Book-64.93Miscellaneous Outstanding Shares131,880,000Free Float121,844,000Market Cap$1.20 billion OptionableOptionable Beta0.83 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:CTIC) was last updated on 10/22/2025 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in JanuaryCurious about crypto but still stuck scrolling endless threads? People who get in early aren’t just lucky—they...Crypto 101 Media | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredA Worldwide Gold Lockdown Is Now UnderwayCentral banks around the world are hoarding gold at one of the fastest rates in history — and former Goldman S...Stansberry Research | SponsoredWhat Wall Street Won’t Say Out LoudDiscover the 7 key indicators before everyone else doesAmerican Alternative | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredTrump cannot stop this trainThe Nobel Committee just confirmed what free-market thinkers have long argued — that true wealth isn’t built t...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CTI BioPharma Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share CTI BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
